Application and Method of a Biomarker in a Reagent for Predicting Radiosensitivity in Colorectal Cancer

By detecting the expression levels of miR-4784 and CACNA1B and combining them with corresponding sensitizing drugs, the shortcomings in predicting radiosensitivity for colorectal cancer were addressed, enabling the development of individualized radiotherapy plans and the optimization of radiotherapy outcomes.

CN123108150APending Publication Date: 2026-11-17BEIJING FRIENDSHIP HOSPITAL CAPITAL MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611372789.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-07
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Current technologies lack effective biomarkers to predict the radiosensitivity of colorectal cancer patients, and lack safe and effective radiosensitizing targets, resulting in large individual differences in radiotherapy efficacy and making it difficult to develop individualized radiotherapy and chemotherapy plans.

Method used

Using miR-4784 and/or CACNA1B as biomarkers, the expression levels of miR-4784 and CACNA1B in colorectal cancer tumor tissues were detected to assess the risk of radiotherapy tolerance in patients, and corresponding sensitizing drugs such as miR-4784 inhibitors and CACNA1B overexpression vectors were developed for the preparation of radiosensitizing drugs for colorectal cancer.

Benefits of technology

It enables rapid and convenient preoperative assessment of patients' radiotherapy tolerance risk, reduces bodily damage and waste of medical resources caused by ineffective radiotherapy, and provides a new intervention approach to improve tumor radiotherapy resistance and optimize radiotherapy effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123108150A_ABST
    Figure CN123108150A_ABST
Patent Text Reader

Abstract

This invention relates to the application and method of a biomarker in a reagent for predicting radiosensitivity in colorectal cancer, belonging to the field of biomedical technology. It addresses several problems in existing technologies, including the lack of specific molecular biomarkers for radiosensitivity in colorectal cancer, unclear radiosensitization targets, inability to preoperatively predict radiotherapy efficacy, lack of molecular interventions to target and regulate radiotherapy resistance, significant individual variability in the efficacy of traditional radiotherapy regimens, and difficulty in developing individualized radiotherapy and chemotherapy plans. This invention provides the application of a biomarker in the preparation of a reagent for predicting radiosensitivity in colorectal cancer. The biomarker includes miR-4784 and / or CACNA1B. This invention provides molecular assessment indicators for radiosensitivity in colorectal cancer, and the assessment is completed through testing tumor tissue samples. The operation process is simple, and preoperative screening of patients' radiotherapy tolerance risk can be performed, facilitating doctors to develop targeted individualized radiotherapy plans and reducing the damage to the body and waste of medical resources caused by ineffective radiotherapy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biomedical technology, and in particular to the application and method of a biomarker in a reagent for predicting radiosensitivity to colorectal cancer. Background Technology

[0002] Colorectal cancer (CRC) is one of the most common malignant tumors of the digestive system worldwide, ranking among the top malignant tumors in terms of both incidence and mortality. Radiotherapy is one of the important treatment methods for colorectal cancer patients, often used for preoperative neoadjuvant radiotherapy and postoperative adjuvant radiotherapy, which can effectively reduce the local recurrence rate, increase the sphincter preservation rate, and improve patient prognosis.

[0003] However, a major challenge in the clinical application of radiotherapy is the resistance of tumor cells to radiation, i.e., radiotherapy resistance. Some colorectal cancer patients do not respond well to radiotherapy and even experience disease progression, which is closely related to intrinsic or acquired radioresistance mechanisms in tumor cells. The development of radioresistance involves complex molecular biological processes, including enhanced DNA damage repair capabilities, blocked apoptosis pathways, alterations in cell cycle checkpoints, acquisition of tumor stem cell characteristics, and changes in the tumor microenvironment.

[0004] Currently, there is a lack of effective biomarkers in clinical practice to predict the radiosensitivity of colorectal cancer patients, as well as a lack of safe and effective radiosensitizing targets to improve the efficacy of radiotherapy. Therefore, in-depth analysis of the molecular mechanisms of radiotherapy resistance in colorectal cancer and the search for reliable therapeutic targets and predictive biomarkers are of significant clinical importance. Summary of the Invention

[0005] Based on the above analysis, the present invention aims to provide an application and method of biomarkers in a reagent for predicting radiosensitivity in colorectal cancer, in order to solve one of the problems in the prior art, such as the lack of specific molecular biomarkers for radiosensitivity in colorectal cancer, unclear radiosensitization targets, inability to predict the efficacy of radiotherapy before surgery, lack of molecular intervention methods for targeted regulation of radiotherapy resistance, large individual differences in the efficacy of traditional radiotherapy regimens, and difficulty in developing individualized radiotherapy and chemotherapy regimens.

[0006] The first aspect of this invention provides the application of a biomarker in the preparation of a diagnostic reagent for predicting radiosensitivity in colorectal cancer, said biomarker including miR-4784 and / or CACNA1B.

[0007] In a further application, the risk of radiotherapy tolerance in patients is assessed by detecting the expression level of miR-4784 in colorectal cancer tumor tissue; if the normalized RPM expression of miR-4784 in the tumor tissue is higher than the median expression in radiosensitive patients according to TCGA, then the colorectal cancer patient is judged to have poor radiosensitivity and is prone to radiotherapy resistance.

[0008] In a further application, the risk of radiotherapy tolerance in patients is determined by detecting the expression level of CACNA1B mRNA or protein in colorectal cancer tumor tissue. If the standardized TPM expression level of CACNA1B mRNA is lower than the median expression level of radiosensitive patients by TCGA, or if the expression level of CACNA1B protein is lower than the median expression level of radiosensitive patients by TCGA, then the patient is judged to have weak radiosensitivity to colorectal cancer and is prone to radiotherapy resistance.

[0009] The second invention provides a detection kit for predicting radiosensitivity in colorectal cancer, including the specific detection of the expression levels of the aforementioned biomarkers.

[0010] The third invention provides the application of the biomarker according to claim 1 in the preparation of radiosensitizing drugs for colorectal cancer.

[0011] Furthermore, the applications include the use of miR-4784 inhibitors in the preparation of radiosensitizing drugs for colorectal cancer; and / or the use of CACNA1B overexpression vectors or CACNA1B agonists in the preparation of radiosensitizing drugs for colorectal cancer.

[0012] Furthermore, in the aforementioned application, the CACNA1B overexpression vector is any one of a plasmid containing the complete CACNA1B-encoding CDS sequence, a lentiviral vector, or an adeno-associated virus vector.

[0013] Furthermore, in the aforementioned applications, the miR-4784 inhibitor is miR-4784 antagomir, miR-4784 sponge, a CRISPR knockout vector targeting miR-4784, or a miR-4784 antisense oligonucleotide.

[0014] Furthermore, in the aforementioned applications, the radiosensitizing drug can be administered in combination with radiotherapy.

[0015] The fourth invention also provides an in vitro method for predicting radiosensitivity to colorectal cancer, comprising the following steps: Step 1: Detect the expression levels of the above markers in colorectal cancer tumor tissue; Step 2: Determine radiosensitivity based on the expression level; if miR-4784 is highly expressed and / or CACNA1B is lowly expressed, the patient is determined to be radioresistant; if miR-4784 is lowly expressed and / or CACNA1B is highly expressed, the patient is determined to be radiosensitive.

[0016] Compared with the prior art, the present invention can achieve at least one of the following beneficial effects: 1. This invention uses miR-4784 and / or CACNA1B as biomarkers to prepare a radiosensitivity prediction reagent for colorectal cancer, which can compensate for the lack of targeted molecular assessment indicators in current clinical practice. TCGA cohort data show that the expression of miR-4784 is increased and the expression of CACNA1B is decreased in the tumor tissue of radiotherapy-resistant patients. Risk stratification can be completed by using the median expression in the sensitive population of the database as the cutoff value. The supporting reagent kit and in vitro detection method rely on routine clinical detection methods such as qRT-PCR and immunohistochemistry. Only tumor tissue samples are needed to complete the assessment. The operation procedure is simple and can be used to screen patients for radiotherapy tolerance risk before surgery, which facilitates doctors to develop targeted individualized radiotherapy plans and reduce the damage to the body and waste of medical resources caused by ineffective radiotherapy.

[0017] 2. This invention clarifies that miR-4784 can bind to the 3'UTR region of CACNA1B and downregulate its expression, elucidating the molecular pathway by which the two jointly regulate radiosensitivity in colorectal cancer. Compared to traditional assessment methods that rely solely on imaging and routine pathological indicators, this approach is supported by a clear molecular mechanism; risk differentiation can be achieved by detecting miR-4784 or CACNA1B alone, and the combined detection of the two can optimize the stratification reference value. The biomarkers have undergone multi-layered validation through public data screening, dual-luciferase targeting verification, and cell function experiments, demonstrating good target specificity. This can improve the problems of traditional assessment methods lacking molecular basis and having limited predictive value for treatment efficacy.

[0018] 3. This invention provides miR-4784 inhibitors, CACNA1B overexpression vectors, or agonists for the preparation of radiosensitizing drugs for colorectal cancer, offering a new intervention strategy for improving tumor radiotherapy resistance. Cell proliferation and colony formation experiments show that inhibiting miR-4784 function or increasing CACNA1B expression levels can improve the radiosensitivity of colorectal cancer cells. CACNA1B expression can be upregulated through various vectors such as plasmids, lentiviruses, and adeno-associated viruses. miR-4784 exists in various inhibitory forms, including antagomir, sponge, CRISPR knockout vectors, and antisense oligonucleotides, providing a rich variety of formulation options. These sensitizing drugs can be used in combination with radiotherapy, alleviating the limitations of simply increasing radiation dose, which can easily damage normal tissues, and optimizing the overall effect of radiotherapy.

[0019] In this invention, the above-described technical solutions can be combined with each other to achieve more preferred combinations. Other features and advantages of this invention will be set forth in the following description, and some advantages may become apparent from the description or be learned by practicing the invention. The objects and other advantages of this invention can be realized and obtained from what is particularly pointed out in the description and drawings. Attached Figure Description

[0020] The accompanying drawings are for illustrative purposes only and are not intended to limit the invention. Throughout the drawings, the same reference numerals denote the same parts. Figure 1 Box plots of miR-4784 expression levels in the radiosensitive and drug-resistant groups in the TCGA database; Figure 2 Box plots of CACNA1B expression levels in the radiosensitive and drug-resistant groups in the TCGA database; Appendix Figure 3 Radiosensitivity curves for radiosensitive and drug-resistant colorectal cancer cell lines; Figure 3 A is a representative plate / well plate image of the cell colony formation experiment; Figure 3 B is the cell survival curve; Figure 4 A bar chart showing the relative expression levels of CACNA1B mRNA after overexpression of the miR-4784 mimic; Figure 5 The effect of miR-4784 mimics overexpression on CACNA1B protein; Figure 6 The figure shows the experimental results of miR-4784 targeting and binding to CACNA1B and dual-luciferase reporter gene assays. Figure 6 A is a schematic diagram of the target binding site of miR-4784 and CACNA1B 3'UTR. Figure 6 B is a bar chart showing the activity of dual-luciferase reporter genes; Figure 7 A bar chart showing the effect of co-transfection of miR-4784 mimics and CACNA1B overexpression plasmid on the relative proliferation rate of colorectal cancer cells after 6 Gy irradiation. Figure 8 The results of clonogenic experiments and the relative clonogenic rate of colorectal cancer cells after co-transfection with miR-4784 mimics and CACNA1B overexpression plasmid followed by 6 Gy irradiation are presented in a bar chart. Figure 8 A shows photographs of four groups of cell clone colony culture plates. Figure 8 B is a bar chart showing the quantitative statistics of relative clonal formation rate. Detailed Implementation

[0021] Preferred embodiments of the present invention will now be described in detail with reference to the accompanying drawings, which form part of this application and are used together with the embodiments of the present invention to illustrate the principles of the present invention, but are not intended to limit the scope of the present invention.

[0022] The first aspect of the present invention provides the application of a biomarker in the preparation of a diagnostic reagent for predicting radiosensitivity to colorectal cancer, said biomarker including miR-4784 and / or CACNA1B.

[0023] This approach uses miR-4784 and CACNA1B, alone or in combination, as biomarkers to prepare radiosensitivity prediction reagents. Based on TCGA cohort and cell series multilayer validation data, the expression levels of these two molecules are stably associated with the radiotherapy response status of colorectal cancer. They can serve as molecular reference indicators to compensate for the lack of targeted radiotherapy assessment biomarkers in current clinical practice and are suitable for the development of various in vitro detection reagents.

[0024] In a further application, the risk of radiotherapy tolerance in patients is assessed by detecting the expression level of miR-4784 in colorectal cancer tumor tissue; if the normalized RPM expression of miR-4784 in the tumor tissue is higher than the median expression in radiosensitive patients according to TCGA, then the colorectal cancer patient is judged to have poor radiosensitivity and is prone to radiotherapy resistance.

[0025] Using the median RPM expression of miR-4784 in radiosensitive individuals from TCGA as the stratification threshold, a standardized judgment criterion is formed. The risk of radiotherapy tolerance can be distinguished simply by detecting the expression level of miR-4784 in tumor tissue. The judgment criteria are objective and quantitative, reducing the bias caused by subjective judgment in traditional assessment methods and facilitating a unified clinical interpretation logic.

[0026] In a further application, the risk of radiotherapy tolerance in patients is determined by detecting the expression level of CACNA1B mRNA or protein in colorectal cancer tumor tissue. If the standardized TPM expression level of CACNA1B mRNA is lower than the median expression level of radiosensitive patients by TCGA, or if the expression level of CACNA1B protein is lower than the median expression level of radiosensitive patients by TCGA, then the patient is judged to have weak radiosensitivity to colorectal cancer and is prone to radiotherapy resistance.

[0027] Using two detection stratification standards, CACNA1B mRNA (TPM quantification) and protein, it can be matched with a variety of routine clinical detection methods such as qRT-PCR, immunohistochemistry, and Western blot. The detection method can be flexibly selected according to the existing equipment in the laboratory. It relies on standardized median thresholds to achieve radiotherapy drug resistance risk stratification and broaden the clinical application scenarios.

[0028] The second invention provides a detection kit for predicting radiosensitivity in colorectal cancer, including the specific detection of the expression levels of the aforementioned biomarkers.

[0029] The kit is equipped with biomarker-specific detection reagents, which can simultaneously or independently complete the quantitative detection of miR-4784 and CACNA1B expression. There is no need for the laboratory to prepare the detection raw materials. The entire detection system can be standardized and prepared in batches. The detection process is uniform and can stably reproduce the quantitative results of tumor sample biomarkers. It is suitable for medical institutions at all levels to carry out preoperative radiotherapy risk screening.

[0030] The third invention provides the application of the above-mentioned markers in the preparation of radiosensitizing drugs for colorectal cancer.

[0031] Developing radiosensitizing drugs based on the regulatory relationship between miR-4784 and CACNA1B addresses tumor radiotherapy resistance at the molecular pathway level. This approach differs from traditional radiotherapy optimization methods that rely solely on increasing radiation dose, providing a new direction for targeted intervention and enriching the drug development pathway for combined radiotherapy treatment of colorectal cancer.

[0032] Furthermore, the applications include the use of miR-4784 inhibitors in the preparation of radiosensitizing drugs for colorectal cancer; and / or the use of CACNA1B overexpression vectors or CACNA1B agonists in the preparation of radiosensitizing drugs for colorectal cancer.

[0033] Two sensitization development routes are miR-4784 inhibitors and CACNA1B upmodulators. Both types of formulations can be used alone or in combination to prepare drugs. Based on cell proliferation and clonogenic function experiments, both can improve tumor radiosensitivity. The technical solutions are flexible and can be adapted to different drug development processes.

[0034] Furthermore, in the aforementioned application, the CACNA1B overexpression vector is any one of a plasmid containing the complete CACNA1B-encoding CDS sequence, a lentiviral vector, or an adeno-associated virus vector.

[0035] Various mature CACNA1B overexpression vectors, including plasmids, lentiviruses, and adeno-associated virus vectors, can stably carry the complete CACNA1B coding sequence to achieve gene upregulation. These vector systems are all mature tools in the field, reducing the operational difficulty of developing sensitizing agents and validating them in vitro, and the technology is highly reproducible.

[0036] Furthermore, in the aforementioned applications, the miR-4784 inhibitor is miR-4784 antagomir, miR-4784 sponge, a CRISPR knockout vector targeting miR-4784, or a miR-4784 antisense oligonucleotide.

[0037] A variety of mature miR-4784 inhibition tools, including oligonucleotides, vectors, and gene-editing formulations, are available. Different forms of inhibition can downregulate miR-4784 function and relieve its inhibition of CACNA1B. The range of research and development materials is broad, and suitable inhibitory materials can be selected according to the drug administration scenario and cell model.

[0038] Furthermore, in the aforementioned applications, the radiosensitizing drug can be administered in combination with radiotherapy.

[0039] The fourth invention also provides an in vitro method for predicting radiosensitivity to colorectal cancer, comprising the following steps: Step 1: Detect the expression levels of the above markers in colorectal cancer tumor tissue; Step 2: Determine radiosensitivity based on the expression level; if miR-4784 is highly expressed and / or CACNA1B is lowly expressed, the patient is determined to be radioresistant; if miR-4784 is lowly expressed and / or CACNA1B is highly expressed, the patient is determined to be radiosensitive.

[0040] A standardized two-step in vitro detection process has been established, which only requires detecting the expression of tumor tissue markers and comparing them with the rules for determining high and low expression to complete the population stratification. The operation steps are simple, and a stable judgment logic is formed by relying on public databases and cell experiments, which facilitates the rapid completion of radiotherapy sensitivity assessment before clinical surgery and assists in the formulation of individualized radiotherapy plans.

[0041] Example 1: Screening and validation of miR-4784 and CACNA1B from the TCGA database as radiosensitivity markers for colorectal cancer. 1.1 Data Acquisition and Grouping Settings Data on colorectal cancer miRNA transcriptomes, mRNA transcriptomes, and accompanying clinical radiotherapy follow-up were obtained from the TCGA database. Patients were divided into a radiosensitive group (n=14) and a radioresistant group (n=8) based on their radiotherapy response. The radiosensitive group (Complete Response, CR) represents complete remission, indicating the disappearance of all target lesions and is the highest level of treatment effectiveness. The radioresistant group (Progressive Disease, PD) represents disease progression, indicating tumor enlargement or the appearance of new lesions and no response to treatment.

[0042] The criteria for screening differentially expressed genes were set as |log2(Fold Change)|≥1 and P<0.05. The targeting relationship between miRNAs and target mRNAs was predicted using three databases: TargetScan, miRDB, and miRTarbase. Molecules from the predicted intersection were selected as candidate targets. Specifically, for TargetScan 9.0: context++ score percentile≥90; for miRDB 6.0: target score≥80; and for miRTarbase 8.0: the experimental validation database did not require a scoring threshold.

[0043] 1.2 Results of Differential Expression of Biomarkers After screening the intersection of multiple databases, two groups of key differentially expressed molecules were identified: the radiotherapy-resistant group showed significant upregulation of miR-4784 (log2FC=4.06, P<0.001); the radiotherapy-resistant group showed significant downregulation of CACNA1B (log2FC=-5.13).

[0044] like Figure 1 The results showed that miR-4784 was quantified using the RPM method. The expression level in the radiotherapy resistant group was significantly higher than that in the radiotherapy sensitive group (P<0.001). The median RPM of miR-4784 in the PD group was 0.6661, and the median RPM of miR-4784 in the CR group was 0.

[0045] like Figure 2 The results showed that CACNA1B mRNA expression levels were significantly lower in the radiotherapy-resistant group than in the radiotherapy-sensitive group (P < 0.01) using the TP method. Furthermore, TCGA survival analysis indicated that patients with low CACNA1B expression had shorter overall survival. The median TPM in the CACNA1B PD group was 0.1025, and the median TPM in the CACNA1B CR group was 0.2619.

[0046] 1.3 Radiotherapy Risk Stratification Criteria Based on Expression Levels miR-4784 stratification criteria: The median (0) of miR-4784 RPM expression in TCGA radiosensitive patients (CR group) was used as the critical threshold; if the standardized RPM expression value of miR-4784 in colorectal cancer tumor tissue was higher than this median, the patient was judged to have poor radiosensitivity and be prone to radiotherapy resistance.

[0047] CACNA1B stratification criteria: The median TPM expression of CACNA1B mRNA in radiosensitive patients (CR group) of TCGA (0.2619) was used as the critical threshold; if the standardized TPM of CACNA1B mRNA in colorectal cancer tumors is lower than this median, or if the expression level of CACNA1B protein in the tumor is lower than the median of radiosensitive patients, the patient is judged to have weak radiosensitivity and be prone to radiotherapy resistance.

[0048] 1.4 Supporting detection methods for markers The detection methods for miR-4784 include: real-time quantitative PCR (qRT-PCR), Northern blot, in situ hybridization based on LNA probes, gene chip, and RNA sequencing. miR-4784 qRT-PCR upstream and downstream primers: Upstream (5' to 3') is as shown in SEQ ID NO:1, CTGAGGATGAGGAG ATGCTGG; Downstream (5'to3') is as shown in SEQ ID NO:2, GTGCAGGGTCCGAGGT; The LNA in situ hybridization probe is shown in SEQ ID NO:3, TCAGTCCCAGCATCTCCTCA; The detection methods for CACNA1B include: qRT-PCR, Western blot, immunohistochemistry (IHC), gene chip, and RNA sequencing. CACNA1B amplification primers: The upstream (5'to3') is as shown in SEQ ID NO:4, specifically: GGTCTCTGGTG GTTTTGTTCT; The downstream (5'to3') is as shown in SEQ ID NO:5, specifically: AGGAGATTTC CGTTGTGTGG; The amino acid sequence of the IHC primary antibody immunogen is shown in SEQ ID NO:6, specifically: ALMIFDFYKQ NKTTRDQMQQAPGGLSQMGP VSLFHPLKAT LEQTQPAVLR GARVFLRQKS STSLSNGGAI QNQESGIKES VSWGTQRTQDAPHE; Example 2: Dual-luciferase reporter gene assay to verify that miR-4784 directly targets CACNA1B 3'UTR 2.1 Carrier Construction Operation Using pmirGLO dual-luciferase vector as the backbone, two types of recombinant vectors were constructed: The first type is the CACNA1B 3'UTR wild-type vector, which includes CACNA1B 3'UTR-WT1 and CACNA1B 3'UTR-WT2. Both sequences naturally carry the miR-4784 seed binding site. CACNA1B 3'UTR-WT1 nucleic acid sequence such as SEQ ID As shown in NO:7, specifically: gctcaggacactgtccaaggtgcacaagatgctgggaggtcccttgtttggtgaagaaagggagcatttagagcagttgatggtggtgtgtcctccgtgttctgaaattccagatgatctgtgttggattcttggcttctacccc atgattctcctcaaagaaattgtgtgtgatgtgtgtgtgtgtgtgtgtgtgtgtgtgtctgtgtcacaggagatgcagtgcctgtacaggtgtgttcagtgtgtggatgtcattaacccatagggctatgcaacaaaagacacatttaatagaag CACNA1B 3'UTR-WT2 nucleic acid sequence such as SEQ ID As shown in NO:8, specifically: tgaccgctcagacgcctgcatgcagcaggcgtgtgttccagtggatgagttttatcatccacggggcagccggccctcgggggaggccttgcccaccttggtgaggctcctgtggcccctccctccccctcctcccctcttt tactctagacgacgaataaagccctgttagaggatgcggctctctctgtccccttcctgtcctgccttcctgggtctcgtaccacacaccagacctaaaccgcaggctgctgtgtgtgctgagaaggacccaggagtccaaatcccgtgtcctg The second type is the CACNA1B 3'UTR mutant vector, which includes CACNA1B 3'UTR-MU1 and CACNA1B 3'UTR-MU2. It performs site-directed mutations targeting the complementary binding site of miR-4784 to eliminate the pairing sequence between the two.

[0049] CACNA1B 3'UTR-MU1 nucleic acid sequence such as SEQ ID As shown in NO:9, specifically: gctcaggacactgtccaaggtgcacaagatgctgggaggtcccttgtttggtgaagaaagggagcatttagagcagttgatggtggtgtgtcctccgtgttctgaaattccagatgatctgtgttggattcttggcttctaccc catgatgagaagaaaagaaattgtgtgtgatgtgtgtgtgtgtgtgtgtgtgtgtgtgtctgtgtcacaggagatgcagtgcctgtacaggtgtgttcagtgtgtggatgtcattaacccatagggctatgcaacaaaagacacatttaatagaag CACNA1B 3'UTR-MU2 nucleic acid sequence such as SEQ ID As shown in NO:10, specifically: tgaccgctcagacgcctgcatgcagcaggcgtgtgttccagtggatgagttttatcatccacacggggcagccggccctcgggggaggccttgcccaccttggtgaggctcctgtggcccctccctccccagaagaccctcttt tactctagacgacgaataaagccctgttagaggatgcggctctctctgtccccttcctgtcctgccttcctgggtctcgtaccacacaccagacctaaaccgcaggctgctgtgtgtgctgagaaggacccaggagtccaaatcccgtgtcctg 2.2 Cell transfection, grouping, and culture HT29 colorectal cancer cells were selected, and multiple parallel control groups were set up: empty pmirGLO vector group, CACNA1B 3'UTR-WT1+miR-NC group, CACNA1B 3'UTR-WT1+miR-4784 mimics group, CACNA1B 3'UTR-MU1+miR-NC group, and CACNA1B 3'UTR-MU1+miR-4784 mimics group; WT2 and MU2 vectors were simultaneously set up with completely identical control groups.

[0050] miR-NC is a negative control microRNA, and its specific sequence is as follows: The justice chain (5'to3') sequence is shown in SEQ ID NO:11, specifically: UUCUCCGAACGUGUCACGUTT; The antisense chain (5'to3') sequence is shown in SEQ ID NO:12, specifically: ACGUGACACGUUCGGAGAATT; miR-4784 mimics sequence: The justice chain (5'to3') sequence is shown in SEQ ID NO:13, specifically: UGAGGAGAUGCUGGGACUGA; The antisense strand (5'to3') sequence is shown in SEQ ID NO:14, specifically: AGUCCCAGCAUCUCCUCAUU; Transfection reagent brand and model: jetPRIME® Transfection Reagent (101000046); Plasmid transfection dosage: The final concentration of the drug is 1 μg / mL, depending on the culture system. miRNA transfection dosage: final concentration 50 nM; Cell culture incubator parameters: 37℃, 5% CO2, relative humidity ≥95%; After all vectors and miRNAs were co-transfected, the cells were cultured at a constant temperature for 48 hours.

[0051] 2.3 Luciferase Activity Detection Procedure After culture, cells from each group were lysed, and the luminescence intensity of firefly luciferase and Renilla luciferase was detected simultaneously. The Renilla luciferase signal was used as an internal reference for calibration, and the relative luciferase activity (RLA) of each group was calculated.

[0052] like Figure 6 ( Figure 6 A and Figure 6 As shown in B), the experimental results showed that the relative luciferase activity of the co-transfected group of CACNA1B 3'UTR-WT2 and miR-4784 mimics was only 60% of that of the negative control group (P < 0.001); while the co-transfected group of CACNA1B 3'UTR-MU2 and miR-4784 mimics showed no significant downregulation of activity, proving that miR-4784 directly inhibits CACNA1B expression through the 3'UTR binding sequence.

[0053] Example 3: Cellular function experiments to verify that miR-4784 targets CACNA1B to regulate radiosensitivity in colorectal cancer 3.1 Methods for constructing radiotherapy-resistant cell lines Parental colorectal cancer cells of HT29 were selected for fractionated continuous irradiation to establish a radioactive model. The irradiation equipment used a cobalt-60 (60Co) radiation source. The single irradiation dose was 2 Gy, irradiated 5 times a week for 4 consecutive weeks, to obtain a stable radiotherapy-resistant subline HT29-40 Gy. The cell culture conditions were set at 37℃, 5% CO2, and relative humidity ≥95%.

[0054] Appendix Figure 3 Cell survival curve parameters: parental HT29 cells D0 (mean lethal dose) = 1.242; drug-resistant HT29-40Gy cells D0 = 2.753. The mean lethal dose of drug-resistant cells is significantly increased, indicating radiotherapy resistance.

[0055] 3.2 Cell transfection group design Three experimental systems were set up using radiosensitive HT29 cells: Blank control group: transfected miR-NC negative control + blank pcDNA3.1 plasmid; miR-4784 overexpression group: transfected with miR-4784 mimics + blank pcDNA3.1 plasmid; Functional recovery group: transfected with miR-4784 mimics+pcDNA3.1-CACNA1B plasmid. This plasmid only carries the CACNA1B encoding CDS sequence and does not contain the 3'UTR region that miR-4784 targets and binds to, and is not inhibited by miR-4784.

[0056] 3.3 Cell proliferation experiment after 6Gy γ-ray irradiation After transfection, cells from each group were plated in 96-well plates and irradiated with 6 Gy γ rays. On day 4 after irradiation, the OD450 absorbance of the cells was measured using the CCK-8 or MTS method.

[0057] like Figure 7 As shown, the cell proliferation rate in the miR-4784 overexpression group was 1.2 times that of the blank control group (P < 0.01); the cell proliferation rate in the functional recovery group decreased by 12% compared with the miR-4784 overexpression group (P < 0.05).

[0058] 3.4 Colony formation experiment after 6 Gy γ-ray irradiation Cells in each group were irradiated with 6 Gy γ rays 24 h after transfection. After irradiation for 24 h, the cells were digested and re-plated. They were cultured for 10–14 days until the clones were visible to the naked eye. After fixation and staining, the number of clones was counted and the relative clone formation rate of each group was calculated.

[0059] like Figure 8 ( Figure 8 A and Figure 8 As shown in B), the clone formation rate of the miR-4784 overexpression group was 1.27 times that of the blank control group (P < 0.05); the clone formation rate of the functional recovery group was 64% lower than that of the miR-4784 overexpression group (P < 0.05).

[0060] 3.5 miR-4784 regulates CACNA1B at the molecular level. like Figure 4 As shown in the figure, after transfection with miR-4784 mimics, the expression level of CACNA1B mRNA in cells was significantly downregulated by qRT-PCR (P < 0.05). like Figure 5 As shown in the Western blot results, the expression level of CACNA1B protein in cells decreased synchronously after transfection with miR-4784 mimics.

[0061] 3.6 Types of radiosensitizing agents miR-4784 inhibitors: miR-4784 antagomir (final concentration: 100 nM; administration timeline: irradiation 24 h post-transfection, detection 48 h post-irradiation), miR-4784 sponge (final concentration: 1 μg / mL; administration timeline: irradiation 24 h post-transfection, detection 48 h post-irradiation), miR-4784-targeting CRISPR / Cas9 knockout vector (final concentration: 2 μg / mL; administration timeline: screening 48 h post-transfection, detection 48 h post-irradiation), miR-4784 antisense oligonucleotide (final concentration: 100 nM; administration timeline: irradiation 24 h post-transfection, detection 48 h post-irradiation). Modulation agents for CACNA1B: plasmid carrying the complete CDS sequence of CACNA1B (final concentration of administration: 1 μg / mL; administration timeline: irradiation 24 h post-transfection, detection 48 h post-irradiation), lentiviral vector (viral titer: MOI=10; administration timeline: irradiation 24 h post-transfection, detection 48 h post-irradiation), and adeno-associated virus vector (viral titer: MOI=1×10⁻⁶). 4 Administration sequence: irradiation 24 h after transfection, detection 48 h after irradiation).

[0062] Administration of the formulation: The above-mentioned radiosensitizing drugs can be administered in combination with radiotherapy to improve tumor radiosensitivity by upregulating CACNA1B, without the need to simply increase the radiation dose.

[0063] The above description is only a preferred embodiment of the present invention, but the scope of protection of the present invention is not limited thereto. Any changes or substitutions that can be easily conceived by those skilled in the art within the scope of the technology disclosed in the present invention should be included within the scope of protection of the present invention.

Claims

1. Use of a marker in the manufacture of a test for predicting radiosensitivity of colorectal cancer, characterized in that, The markers include miR-4784 and / or CACNA1B.

2. Use according to claim 1, characterized in that, The risk of radiotherapy tolerance in patients is assessed by detecting the expression level of miR-4784 in colorectal cancer tumor tissue. If the normalized RPM expression of miR-4784 in the tumor tissue is higher than the median expression in radiosensitive patients as measured by TCGA, then the patients with colorectal cancer are considered to have poor radiosensitivity and are prone to developing radiotherapy resistance.

3. Use according to claim 1, characterized in that, The risk of radiotherapy tolerance in patients is assessed by detecting the expression level of CACNA1B mRNA or protein in colorectal cancer tumor tissue. If the normalized TPM expression level of CACNA1B mRNA is lower than the median expression level of radiosensitive patients by TCGA, or if the expression level of CACNA1B protein is lower than the median expression level of radiosensitive patients by TCGA, then the patient is considered to have weak radiosensitivity to colorectal cancer and is prone to developing radiotherapy resistance.

4. A test kit for predicting radiosensitivity of colorectal cancer, characterized by comprising the polypeptide of claim 1 or 2 as an active ingredient. This includes the specific detection of the expression level of the biomarker described in claim 1.

5. The use of the biomarker according to claim 1 in the preparation of radiosensitizing drugs for colorectal cancer.

6. Use according to claim 5, characterized in that, This includes the use of miR-4784 inhibitors in the preparation of radiosensitizing drugs for colorectal cancer; and / or the use of CACNA1B overexpression vectors or CACNA1B agonists in the preparation of radiosensitizing drugs for colorectal cancer.

7. The application according to claim 6, characterized in that, The CACNA1B overexpression vector is any one of a plasmid containing the complete CACNA1B coding CDS sequence, a lentiviral vector, or an adeno-associated virus vector.

8. The application according to claim 6, characterized in that, The miR-4784 inhibitor is miR-4784antagomir, miR-4784 sponge, a CRISPR knockout vector targeting miR-4784, or a miR-4784 antisense oligonucleotide.

9. The application according to claim 5, characterized in that, The radiosensitizing drug can be administered in combination with radiotherapy.

10. A method for predicting radiosensitivity to colorectal cancer in vitro, characterized in that, Includes the following steps: Step 1: Detect the expression level of the biomarker as described in claim 1 in colorectal cancer tumor tissue; Step 2: Determine radiotherapy sensitivity based on the expression levels; if miR-4784 is highly expressed and / or CACNA1B is lowly expressed, the patient is determined to be radiotherapy resistant. If miR-4784 is expressed at low levels and / or CACNA1B is expressed at high levels, the patient is considered to be radiosensitive.